Lastest News


Samsung Bioepis starts to develop new drug for acute pancreatitis

Samsung Bioepis(CEO/President Han-Seung Ko) will start to develop new drugs for acute pancreatitis. Samsung Bioepis said they would conduct a Phase I clinical trial for an acute pancreatitis therapy candidate(project...

Bayer resumes supplying Aspirin Tab 500mg in Korea

Bayer Korea(CEO Ingrid Drechsel) announced to gradually resume supplying Bayer’s pain, fever or inflammation treatment Aspirin Tab 500mg in Korea starting today(10th). Bayer Korea discovered some of the Bayer Aspirin...

Will Valsartan incident largely impact on medium-sized pharmas?

The antihypertensive Valsartan incident has been spread widely. The pharmaceutical industry thinks, particularly, the incident will not only become a problem with Chinese Valsartan ingredients but impact the entire Ch...

‘Chung Ang University Hospital’ chosen by patients for best medical service

At an evaluation on medical services by patients, Chung-Ang University Hospital achieved the top position. This was unveiled at the ‘patient-experienced medical service evaluation’ result published by the Ministry of...

How well ‘Big 5’ hospitals did in patient evaluation?

At the patient experience evaluation that was first unveiled, Asan Medical Hospital and the Catholic University of Korea Seoul St. Mary’s Hospital had a good report card among the ‘Big 5’ hospitals. While getting ung...

Patients give 83.9 points on average for medical services they received

The average score patients evaluated medical services in person was 83.9 points. The average score patients evaluated the medical services they had was 83.9 points. The average for both of the doctors’ service and ad...

New insulin ‘Fiasp’ acts 2 twice faster than other insulin products

Fiasp(generic name: insulin aspart), a new regular insulin has raised expectation even before launching with its fast-acting feature. Fiasp is an ultra-fast-acting insulin which effectively and safely control blood s...

“We accept necessity of adding antacids into the emergency household medicines list”

As necessity of adding antacids in the list of emergency household medicines is accepted, they will discuss about which specific products to add in the list. The Ministry of Health and Welfare(Minister Neung-Hoo Park...

Samsung Group, “We’ll make biopharmaceutical field as the next semiconductor business”

Samsung Group will start to aggressively invest funds to make the biologic field to the next semiconductor business. On the 8th, Samsung announced plans to invest total KRW 180 trillion for the next 3 years to contin...

Orphan drugs in development

Under the Orphan Drug Program enforced in 2013, total 18 products have been designated since the year. According to the Ministry of Health and Welfare(MFDS), the government has introduced and enforced the Orphan Drug...

Pharmacy society has a hard time when returning Chinese ‘Valsaltan’ ingredients

In a process of exchanging drugs containing Valsartan ingredients with carcinogenic factors, pharmacies are having trouble with patients over calculating patient-sharing expenses. According to the pharmacy society, b...

Celltrion makes KRW 263.4 billion sales in 2nd quarter

On the 8th, Celltrion gave a notice about the company’s 2018 2nd quarter consolidated business performance that they had a 7% increase to KRW 263.4 billion sales, but a 21.7% decrease to KRW 108.2 billion operating pr...

‘Final meeting’ for emergency household medicines starts finally

The final meeting arranged to adjust emergency household medicine products was held after the long postponement for 1 year and 6 months. The Ministry of Health and Welfare(MOHW) held the ‘6th Deliberative Committee f...

MFDS extensively develop QbD mode to raise competitiveness of pharma industry

The Ministry of Food and Drug Safety(MFDS) will extensively develop the ‘Quality by Design(QbD) system’ model to strengthen completeness of the Korean pharmaceutical industry. Quality by Design, a new paradigm in dru...

Celltrion starts Phase I and Phase III clinical trials for Humira biosimilar

Celltrion recently announced that they made a clinical trial application for ‘CT-P17,’ a biosimilar referencing the rheumatoid arthritis therapy ‘Humira(generic name: adalimumab),’ to the U.K. Medicines and Healthcare...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.